×
About 6,565 results

ALLMedicine™ Glioblastoma Multiforme Center

Research & Reviews  2,346 results

PLGA-nano-encapsulated Disulfiram inhibits hypoxia-induced NFκB, cancer stem cells and ...
https://doi.org/10.1158/1535-7163.MCT-22-0066
Molecular Cancer Therapeutics; Kannappan V, Liu Y et. al.

May 18th, 2022 - Glioblastoma stem cell (GSC) is the major cause of glioblastoma multiforme (GBM) chemotherapy failure. Hypoxia is one of the determinants of GSC. NFκB plays a pivotal link between hypoxia and cancer stem cells (CSCs). Disulfiram (DS), an antialcoh...

The Role of NRF2/KEAP1 Pathway in Glioblastoma: Pharmacological Implications.
https://doi.org/10.1007/s12032-022-01693-0
Medical Oncology (Northwood, London, England); Shahcheraghi SH, Salemi F et. al.

May 15th, 2022 - Glioblastoma multiforme (GBM) grade IV glioma is the most frequent and deadly intracranial cancer. This tumor is determined by unrestrained progression, uncontroled angiogenesis, high infiltration and weak response to treatment, which is chiefly b...

Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Pro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102128
Technology in Cancer Research & Treatment; Wang J, Yan S et. al.

May 12th, 2022 - Glioblastoma multiforme (GBM) is the most malignant primary brain tumor in adults. This study aimed to identify significant prognostic biomarkers related to GBM. We collected 3 GBM and 3 healthy human brain samples for transcriptome and proteomic ...

A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of G...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086421
Journal of Experimental & Clinical Cancer Research : CR; Song J, Zheng J et. al.

May 11th, 2022 - RNA-binding proteins (RBPs) and circular RNAs (circRNAs) play important roles in glioblastoma multiforme (GBM). Aerobic glycolysis is a metabolic characteristic of GBM. However, the roles of RBPs and circRNAs in aerobic glycolysis in GBM remain un...

BG & TMZ Therapy of Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT01269424

May 10th, 2022 - OBJECTIVES: Primary To evaluate the feasibility of introducing and expressing P140K MGMT cDNA from a lentiviral-based provirus in autologous hematopoietic stem cells harvested from Glioblastoma multiforme (GBM) patients. To assess the safety assoc...

see more →

Guidelines  1 results

The role of radiotherapy in the management of progressive glioblastoma : a systematic r...
https://doi.org/10.1007/s11060-013-1337-6
Journal of Neuro-oncology; Ryu S, Buatti JM et. al.

Apr 15th, 2014 - Can re-irradiation (by using conventional radiotherapy, fractionated radiosurgery, or single fraction radiosurgery) be used in patients with progressive glioblastoma multiforme after the first adjuvant combined multimodality treatment with radiati...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  155 results

BG & TMZ Therapy of Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT01269424

May 10th, 2022 - OBJECTIVES: Primary To evaluate the feasibility of introducing and expressing P140K MGMT cDNA from a lentiviral-based provirus in autologous hematopoietic stem cells harvested from Glioblastoma multiforme (GBM) patients. To assess the safety assoc...

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
https://clinicaltrials.gov/ct2/show/NCT04782609

May 9th, 2022 - This is a 2-part multicenter Phase 1b study designed to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation des...

6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)
https://clinicaltrials.gov/ct2/show/NCT04926168

May 6th, 2022 - Recent phase III trials in patients with newly diagnosed patients with glioblastoma have demonstrated that adding new agents (such as cilengitide, bevacizumab, or nivolumab) to standard radiation and TMZ do not improve survival in this disease. Th...

Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT01535911

May 2nd, 2022 - Summary: The current standard of care for glioblastoma multiforme (GBM), the most common primary brain tumor in adults, includes surgical resection, radiation and chemotherapy. Survival rarely exceeds 18 months. The investigators propose to test t...

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT02152982

Apr 29th, 2022 - PRIMARY OBJECTIVE: I. Test whether the experimental combination of ABT-888 (veliparib) combined with TMZ (temozolomide), compared to the control of placebo combined with TMZ, significantly extends overall survival in newly diagnosed glioblastoma m...

see more →

News  118 results

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
https://www.onclive.com/view/fda-grants-fast-track-designation-to-cynk-101-for-her2-gastric-gej-cancers

Jan 19th, 2022 - The FDA has granted a fast track designation to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab (Herceptin), and pembrolizumab (Keytruda) for patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ)...

FDA Grants Fast Track Designation to ST101 for Recurrent Glioblastoma
https://www.onclive.com/view/fda-grants-fast-track-designation-to-st101-for-recurrent-glioblastoma

Dec 6th, 2021 - The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma, according to an announcement from Sapience Therapeutics, Inc., the drug developer.1 The decision is ...

Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma Imaging
https://www.onclive.com/view/advanced-3d-mri-technology-marks-a-leap-forward-in-glioblastoma-imaging

Oct 6th, 2021 - Hui-Kuo Shu, MD, PhD Associate Professor Although advances have been made in imaging techniques for patients with glioblastoma multiforme (GBM), new tools are needed to supplement standard imaging sequences. Researchers at the Winship Cancer...

Dendritic Cell Vaccines Offer Promising Signals as Glioblastoma Therapy
https://www.onclive.com/view/dendritic-cell-vaccines-offer-promising-signals-as-glioblastoma-therapy

Oct 6th, 2021 - Arnold Etame, MD, PhD Moffitt Cancer Center Neuro- Oncology Program Tampa, FL Immunotherapy is rapidly emerging as a very attractive and novel therapeutic approach for cancer, including for glioblastoma multiforme (GBM), the most common...

see more →

Patient Education  1 results see all →